ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Medicine, Research & Experimental |
Manuscript Type |
Minireviews |
Article Title |
Combined targeted therapy and immunotherapy for cancer treatment
|
Manuscript Source |
Invited Manuscript |
All Author List |
Cheng-Xiang Guo, Xing Huang, Jian Xu, Xiao-Zhen Zhang, Yi-Nan Shen, Ting-Bo Liang and Xue-Li Bai |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
the National Key Research and Development Program of China |
2019YFC1316000 |
the National High Technology Research and Development Program of China |
2015AA020405 |
the National Natural Science Foundation of China |
81672337 |
China Postdoctoral Science Foundation |
2020M671761 |
|
Corresponding Author |
Xue-Li Bai, MD, PhD, Chief Doctor, Executive Vice President, Professor, Research Scientist, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road , Hangzhou 310003, Zhejiang Province, China. shirleybai@zju.edu.cn |
Key Words |
Cancer; Targeted therapy; Immunotherapy; Combined treatment |
Core Tip |
There has been considerable interest in combining systemic and immune-related therapies for the anti-tumor treatment of various cancer types. Additional insights into the effects and mechanisms of targeted therapies on the induction of antitumor immunity will aid the development and design of rational and effective combination strategies, with the synergistic potential for rapid tumor regression and a durable response. Alternatively, targeting specific signaling pathways may also help in overcoming the mechanisms of immunotherapy resistance. In this study, we briefly review the immunomodulatory effects of combinations of targeted therapies and immunotherapies, and discusses the obstacles associated with them, which may be useful for the development of novel basic research or clinical trials. |
Publish Date |
2021-09-10 07:23 |
Citation |
Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 |
URL |
https://www.wjgnet.com/2307-8960/full/v9/i26/7643.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v9.i26.7643 |